Drug profile · INN
epcoritamab-bysp
EPKINLY
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
epcoritamab-bysp (EPKINLY) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN epcoritamab-bysp
Brand EPKINLY
Route SUBCUTANEOUS
Formulation INJECTABLE
Frequently asked questions
What is epcoritamab-bysp?
epcoritamab-bysp (EPKINLY) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for epcoritamab-bysp?
EPKINLY is a marketed brand name for epcoritamab-bysp. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of epcoritamab-bysp?
epcoritamab-bysp has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.